Healthcare shares were generally flat in pre-market trade
In healthcare stocks news, EntreMed (
) reported a wider net loss in Q4 than the year earlier, mainly
because it didn't receive royalties from the sale of Celgene's (
) leprosy skin sores drug Thalomid.
The clinical-stage pharmaceutical company said its Q4 loss was
$1.3 million or $0.05 per share compared to $0.4 million or $0.02
per share the year earlier. The company had no sales in the
quarter, which it said was expected, compared to $0.7 million in
royalties from Thalomid the year earlier. No analyst estimates were
available for comparison.
And, Sangamo Biosciences (
) shares slipped nearly 2% in recent
on Friday after the biopharmaceutical company late Thursday priced
its brokered public offering of 4.4 million common shares at $22.50
each, for gross proceeds of $100 million.
Underwriters have also been granted a 30-day option to buy an
additional 666,666 shares of common stock.
Net proceeds from the offering will be used for working capital
and general corporate purposes.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.